RANITIDINE TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

RANITIDINE (RANITIDINE HYDROCHLORIDE)

제공처:

PRO DOC LIMITEE

ATC 코드:

A02BA02

INN (International Name):

RANITIDINE

복용량:

300MG

약제 형태:

TABLET

구성:

RANITIDINE (RANITIDINE HYDROCHLORIDE) 300MG

관리 경로:

ORAL

패키지 단위:

100/30

처방전 유형:

Prescription

치료 영역:

HISTAMINE H2-ANTAGONISTS

제품 요약:

Active ingredient group (AIG) number: 0115150001; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2023-07-10

제품 특성 요약

_ _
RANITIDINE_ _
_Page 1 of 28_
PRODUCT MONOGRAPH
PR RANITIDINE
Ranitidine Tablets, USP
150 mg & 300 mg ranitidine (as ranitidine hydrochloride)
Histamine H
2
-receptor antagonist
PRO DOC LTÉE
2925, boul. Industriel
Laval, Quebec
H7L 3W9
Date of Revision:
September 18, 2019
Submission Control No: 229390
RANITIDINE_ _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
................................................................................13
PHARMACEUTICAL INFORMATION
..........................................................................13
CLINICAL TRIALS
..........................................................................................................14
DETAILED PHARMACOLOGY
................